Iminosugars are known as inhibitors of glucosidases and glycosphingolipid metabolism. We here demonstrate that the iminosugar AMP-DNM, besides potently improving glucose homeostasis, stimulates satiety and activates brown adipose tissue (BAT) in diabetic obese rodents via glucagon-like peptide-1 (GLP1). Orally administered AMP-DNM increased systemic GLP1 concentrations and concomitantly activated hypothalamic and brainstem anorexigenic neurons. AMP-DNM failed to promote satiety and activate BAT in obese mice lacking the brain GLP1 receptor (GLP1r), as well as in obese wild-type animals treated intracerebroventricularly with the GLP1r reverse agonist exendin-9. Evidence is provided for induction of GLP1 release through interaction of AMP-DNM with bitter taste receptors in entero-endocrine cells. Beneficial effects of AMP-DNM on insulin sensitivity, glycemic control, resting energy expenditure and fat mass were not exclusively mediated by the GLP1 system. In conclusion, the anti-diabetic iminosugar AMP-DNM improves satiety and activates BAT largely through GLP1 in rodent models of the metabolic syndrome.
INTRODUCTION
Obesity, taking worldwide epidemic proportions, is accompanied by development of metabolic syndrome, which can result in metabolic diseases including type 2 diabetes. Besides existing cognitive-behavioral treatments and surgical interventions, improved pharmacological agents with long-term efficacy are in demand. Iminosugars are sugar analogues in which nitrogen replaces the oxygen in the ring structure. As mimics of sugar transition states during reactions catalyzed by glycosidases and glycosyltransferases, iminosugars may act as potent inhibitors (Wennekes et al., 2009 ). Numerous natural and synthetic iminosugars have been shown to inhibit enzymes involved in the metabolism of glycosphingolipids (GSLs) (Aerts et al., 2011) . Excessive GSLs are implicated in the onset of metabolic comorbidities of obesity (Aerts et al., 2011; Wennekes et al., 2009 ). The well tolerated amphiphilic iminosugar N-adamantane-methyloxypentyl-deoxynojirimycin (AMP-DNM) inhibits biosynthesis of glucosylceramide and consequently reduces GSLs. AMP-DNM markedly improves glucose homeostasis in obese rodents through a dual mechanism. It buffers carbohydrate assimilation via inhibition of intestinal glycosidases and concomitantly improves insulin responsiveness by reducing excessive GSLs surrounding the insulin receptor (Aerts et al., 2007; Wennekes et al., 2010) . AMP-DNM also reduces inflammation of adipose tissue and corrects hepatosteatosis (Aerts et al., 2011; Bijl et al., 2009; van Eijk et al., 2009 ). Moreover, oral administration of AMP-DNM normalizes food intake in obese rodents (mice and rats alike), even in animals lacking leptin or its receptor (Langeveld et al., 2012) . It is widely documented that signals secreted by peripheral tissues influence orexigenic and anorexigenic hypothalamic neurons that control food intake, energy expenditure and insulin sensitivity (Munzberg et al., 2016) . We hypothesized that AMP-DNM impacts endocrine-neuronal interactions involved in regulation of satiety and body metabolism. In particular, we considered induction of gut hormone GLP1 by AMP-DNM, which is known to induce metabolic actions by interacting with its receptors expressed on neurons in the gut and the brain (Cabou and Burcelin, 2011) . We here report the systemic release of GLP1 by orally administered AMP-DNM and the involvement of the central GLP1r in the induction of satiety and the activation of brown adipose tissue (BAT). Evidence is provided for the role of intestinal bitter taste receptors in the activation of the beneficial GLP1 pathway by AMP-DNM. Figure 1A ) inhibits biosynthesis of glucosylceramide and GSLs (Overkleeft et al., 1998; Wennekes et al., 2010; Wennekes et al., 2009 ). We studied the effects of peripheral intragastric (ig) and central intracerebroventricular (icv) administration of AMP-DNM in lean and obese rats. Food intake during 5 days was not changed by ig administration of AMP-DNM ( Figure 1B ). The respiratory exchange ratio (RER) was decreased ( Figure 1C ), fat oxidation was increased ( Figure 1D ), and body weight gain was reduced ( Figure 1F ). Energy expenditure (data not shown), locomotor activity (data not shown) and plasma glucose ( Figure 1E ) in lean rats were not changed by ig treatment. Obese diabetic ZDF rats showed very similar responses. AMP-DNM administered ig decreased daily food intake ( Figure 1G ), decreased RER ( Figure 1H ), increased fat oxidation rate ( Figure 1I ), and reduced body weight gain ( Figure 1K ). Hyperglycemia was lowered in obese ZDF rats re-
RESULTS

AMP-DNM decreases food intake in obese rats through peripheral action.
AMP-DNM (
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ceiving AMP-DNM ( Figure 1J ). To establish whether the metabolic improvements in the ad libitum ig AMP-DNM treated obese ZDF rats were caused by their decreased food intake, an additional group was pair-fed (PF). RER was lower in PF animals ( Figure S1A ) and body weight gain tended to be less (p=0.051) ( Figure S1B ). However, PF animals did not show the changes in fat oxidation ( Figure S1C ) and plasma glucose ( Figure S1D ) imposed by AMP-DNM. Clearly, not all metabolic improvements induced by AMP-DNM in the obese rats can be ascribed to reduced food intake. To determine whether the observed improvements induced by AMP-DNM are due to a direct action in the brain, icv infusions of AMP-DNM were performed in lean and obese rats. None of the investigated parameters were significantly changed ( Figure S1E-S1N) . Thus, AMP-DNM acts peripherally to increase fatty acid substrate utilization and decrease body weight gain in lean as well as obese rats. 
AMP-DNM increases active GLP1 in plasma and decreases fasting-induced food intake.
Based on the finding that AMP-DNM influences metabolism uniquely when administered ig, we hypothesized that it may influence gastrointestinal endocrine factors. Indeed, a significantly increased plasma concentration of active GLP1 was observed in lean rats at 20, 40 and 60 minutes' post-infusion of AMP-DNM ( Figure 1L ). Simultaneously, AMP-DNM treated lean rats showed decreased food intake during 2 hours after ig administration ( Figure 1M ). Similar effects occurred after AMP-DNM ig administration in obese ZDF rats. Plasma concentrations of active GLP1 were higher over time ( Figure 1N ) and the higher plasma GLP1 was accompanied with reduced refeeding after fasting ( Figure 1O ). Thus, AMP-DNM stimulates the secretion of active GLP1 in lean and obese rats, accompanied by decreased food intake.
AMP-DNM stimulates hypothalamic and brainstem anorexigenic peptide expression.
It is widely documented that brain is a key player in the control of food intake, thus we next examined whether ig administration of AMP-DNM causes activation of brain areas related to energy metabolism by analyzing C-Fos protein expression in brains of lean and obese ob/ob mice after ig administration of AMP-DNM. AMP-DNM increased C-Fos immunoreactivity (IR) in the hypothalamic arcuate nucleus (ARC) of lean and ob/ob mice ( Figure 2A and 2B), as well as in the dorsomedial hypothalamic nucleus (DMH) ( Figure 2C and 2D) . Also in the brainstem the nucleus of the tractus solitaris (NTS) showed a significant C-fos activation after AMP-DNM administration in both lean and ob/ob mice ( Figure 2E and 2F). A significantly higher activation of C-Fos in the ARC and DMH of ob/ob compared to lean mice ( Figure 2A and 2C) was also observed, such a higher increase was not observed in the NTS ( Figure 2E ). Double immunofluorescence revealed that part of the activated neurons in the ARC was positive for pro-opiomelanocortin (POMC) ( Figure S2A and S2B) and part of neurons in the NTS was positive for GLP1 ( Figure S2C and S2D) . Next, we studied microdissected ARC, DMH, lateral hypothalamus (LH) and NTS of lean and ob/ob mice ig infused with AMP-DNM ( Figure S2E and S2F). Neuropeptide Y (NPY), Agouti-related peptide (AgRP) and POMC expression in the ARC of lean mice did not differ after AMP-DNM administration, however, the ARC of ob/ob animals showed significantly reduced NPY expression and increased POMC expression levels ( Figure 2G ). In the DMH of AMP-DNM treated ob/ob mice, but not lean mice, a significant decrease of glutamate decarboxylase 2 (GAD2) expression was observed ( Figure 2H ). Expression of NPY did not differ in the DMH of AMP-DNM treated ob/ob and lean mice. Likewise, in the LH of lean and ob/ob mice, the expression of NPY, GAD2, Orexin and Melanin-concentrating hormone was not changed by AMP-DNM treatment ( Figure 2I ). Finally, expression of Preproglucagon (PPG) in the NTS was found to be increased after AMP-DNM administration in lean and ob/ob mice ( Figure 2J ). In conclusion, hypothalamic-brainstem anorexigenic circuits, including the ARC, DMH and NTS, were significantly affected by AMP-DNM administered by gavage. 
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AMP-DNM improves signs of metabolic syndrome in diet-induced obese mice.
Next we investigated the effects of AMP-DNM in high fat diet-induced obese (DIO) mice, including an additional pair-fed group. DIO mice fed with AMP-DNM containing diet presented a significantly reduced food intake ( Figure 3A) . The increase in satiety induced by AMP-DNM was accompanied by a significant decrease in body weight gain that exceeded that in the PF group (p=0.01) ( Figure 3B ). Analysis of body composition showed a significant decrease in fat mass gain and a decreased gonadal WAT weight (gWAT) in the AMP-DNM group, but not in the PF group ( Figure 3C, 3D ). These data suggest that AMP-DNM decreases WAT mass and body weight via mechanisms different from decrease of food intake. DIO mice fed with AMP-DNM showed significantly decreased plasma glucose levels after fasting (p<0.0001) compared to the DIO mice fed with HFD (t=0 in Figure 3E ). Oral glucose tolerance test (OGTT) revealed that the AMP-DNM fed group presented a significantly higher glucose sensitivity that was only partly dependent of decreased food intake as was revealed by comparison with pair fed mice ( Figure 3E, 3F) . 
AMP-DNM stimulates BAT activity in diet-induced obese mice.
BAT activation is known to improve glucose metabolism and decrease body weight in obese animals (Bartelt and Figure 3G and 3H). The increased glucose and TG-derived fatty acid uptake in the BAT of AMP-DNM fed mice were accompanied by a trend of decreased iBAT weight ( Figure 3I ) and significantly decreased lipid droplet content ( Figure 3J ). These findings suggest that chronic administration of AMP-DNM stimulates glucose and fatty acid uptake in iBAT by stimulating combustion of intracellular lipid stores. Increased iBAT activity in DIO mice fed with AMP-DNM was also suggested by an increase of Tyrosine Hydroxylase (TH) signal (p<0.01) ( Figure 3K ), and increased thermogenic gene expression of Ucp-1 and Pgc-1α (p<0.01) ( Figure 3L and 3M).
Absence of brain GLP1r prohibits the satiety promoting effect of AMP-DNM.
Next, we determined the responses to AMP-DNM in wild-type (wt) and GLP1 receptor knockout (GLP1rKO) mice on high fat diet (HFD). AMP-DNM induced a decrease in daily food and water intake in obese wt mice, however, not in GLP1rKO animals ( Figure 4A and 4B). RER was significantly decreased in both wt and GLP1rKO mice fed with AMP-DNM (Figure 4C) . Apparently, GLP1r mediates the satiating effect of AMP-DNM but not the decrease in RER. Body weight losses in wt and GLP1rKO mice were similar after 3 weeks AMP-DNM diet (wt: -2.5g±1.9, GLP1rKO: -4.6g±1.9). GLP1r in the hypothalamus is involved in the beneficial effects of GLP1 on insulin sensitivity, delayed gastric emptying and improved satiety (Barrera et al., 2011) . To test the potential role of central GLP1r, conditional Nkx2.1 cre GLP1r flox/flox (GLP1r KD ΔNkx2.1 ) mice and wt animals were studied in their response to AMP-DNM. GLP1r KD ΔNkx2.1 mice express Cre recombinase throughout most hypothalamic neurons expressing the Nkx2. Figure 4M ). DIO wt mice showed decreased daily food and water intake after AMP-DNM administration by the diet. However, GLP1r KD ΔNkx2.1 mice did not reduce their food or water intake after AMP-DNM treatment ( Figure 4D and 4E). This finding suggests that GLP1r in the brain crucially mediates the satiety promoting effect of AMP-DNM. AMP-DNM treatment improved glucose homeostasis in DIO wt and GLP1r KD ΔNkx2.1 mice in quite similar manner, as reflected by fasting glucose and OGGT assessment ( Figure 4G and 4H). 
Figure 4. Brain GLP1r mediates the satiety effect and hypothalamic activation induced by AMP-DNM in obese mice. Mice were fed with or without AMP-DNM in high fat diet (see experimental). A) Daily food intake of wt and
Inverse agonist of brain GLP1r prohibits the satiety promoting effect of AMP-DNM.
To further substantiate the importance of central GLP1 signaling in the responses to AMP-DNM, DIO wt mice were fed with AMP-DNM (HFD+AMP-DNM) and another group icv infused with exendin-9 (HFD+AMP-DNM+ex9), an inverse agonist of GLP1r (Goke et al., 1993) . Regarding food intake, exendin-9 per se caused no significant changes (HFD: 2.69±0.19 g, HFD+exendin-9: 3.05±0.24 g). However, DIO mice fed with AMP-DNM showed a significantly decrease in food intake that was largely prohibited by icv exendin-9 ( Figure  5A ). These findings further confirm the role of central GLP1r in the reduction of food intake induced by AMP-DNM. Icv exendin-9 did not change the RER reductions by AMP-DNM (data not shown) and also caused no changes in AMP-DNM induced body weight reduction and loss of fat mass and gWAT weight ( Figure 5B, 5C) . Similarly, icv exendin-9 did not affect improved glucose sensitivity by AMP-DNM in DIO wt mice ( Figure 5D , 5E). 
Mice were fed with or without AMP-DNM in high fat diet (see experimental). A) Daily food intake of mice infused with aCSF (HFD+AMP-DNM) or exendin-9 (HFD+AMP-DNM+ex9). B-C) Difference in fat mass and gonadal WAT (gWAT) weight in HFD+AMP-DNM or HF-D+AMP-DNM+ex9 mice. D-E) Plasma glucose levels and area under the curve (AUC) of OGTT in mice after 21 days of diet and simultaneously icv infusion in HFD+AMP-
Brain GLP1r mediates AMP-DNM induced activation of anorexigenic circuits.
Since AMP-DNM administration increased hypothalamic ARC and DMH neuronal activation in ob/ob mice, we comparatively assessed hypothalamic C-Fos activation in wt and GLP1r KD ΔNkx2.1 DIO mice fed with AMP-DNM. DIO wt mice receiving AMP-DNM showed a higher C-Fos activation in the ARC and DMH ( Figure 4I and 4J) . On the other hand, AMP-DNM did not affect C-Fos activation in the ARC and DMH of DIO GLP1r KD ΔNkx2.1 mice on HFD ( Figure 4I and 4J) . Consistently, POMC mRNA expression was higher in the hypothalamus and PPG expression in the brainstem was increased in DIO wt mice fed with AMP-DNM ( Figure 4K and 4L) . These AMP-DNM-induced increases were not observed in the DIO GLP1r KD ΔNkx2.1 mice ( Figure 4K and 4L) , indicating that the brain GLP1r is necessary for the stimulation of brainstem-hypothalamic anorexigenic neuropeptides by AMP-DNM.
Brain GLP1r mediates the stimulation of BAT activity induced by AMP-DNM.
The central GLP1 system has been implicated in the control of BAT activation and thermogenesis (Kooijman et Figure 5F and 5G). Thus, the central GLP1r mediates the increase in glucose and TG uptake in the iBAT induced by AMP-DNM. HFD+AMP-DNM iBAT also showed increased TH signal ( Figure 5H ) and significantly increased thermogenic Ucp-1 and Pgc-1α gene expression ( Figure 5I and 5J) . DIO HFD+AMP-DNM+ex9 mice did not present this as clearly ( Figure 5H-5J) . Icv exendin-9 administration partially blunted the increased sympathetic input and thermogenic gene expression in BAT after AMP-DNM exposure. Of note, in the BAT of DIO GLP1r KD ΔNkx2.1 mice fed with AMP-DNM, no increase in Ucp-1 and Pgc-1α expression was observed ( Figure 4N ). Figure 6A ). L-ido-AMP-DNM inhibits GSLs synthesis on a par to AMP-DNM, but does not decrease food intake. As positive control we used exposure to glutamate, a non-bitter stimulus, causing the expected intracellular Ca 2+ release in GFP and hT2R16 overexpressing cells ( Figure 6B ). Intracellular Ca 2+ release was significantly higher in hT2R16 cells after incubation with salicin ( Figure 6C ). Exposure to AMP-DNM also dose-dependently provoked increased intracellular Ca 2+ responses in the hT2R16 compared to control cells ( Figure 6D ). The intracellular Ca 2+ response coincided with a significant increase of GLP1 in medium of the hT2R16 cells ( Figure 6E ). In contrast, Figure 6G ). AMP-DNM increased Ca 2+ responses and GLP1 release in medium stronger than L-ido-AMP-DNM. Of note, L-ido-AMP-DNM ig or icv treatment did not show any significant changes in the metabolic parameters measured in lean rats or obese ZDF rats, except for a decrease in plasma glucose levels in the obese ZDF rats after ig administration ( Figure S3A-S3P) .
AMP-DNM stimulates GLP1 secretion through stimulation of bitter receptors in endo-
8
We next overexpressed the hT2R16 mouse orthologue receptors T2R116 and T2R118 in STC1 cells. While AMP-DNM did not increase the Ca 2+ response and GLP1 in medium of T2R116 overexpressing cells (data not show), it did in T2R118 overexpressing cells ( Figure  6H and I) . In contrast, exposure of the same cells to L-ido-AMP-DNM did not elicit Ca 2+ responses or increased secretion of GLP1 (data not show). Thus, AMP-DNM can specifically stimulate GLP1 secretion by entero-endocrine cells in culture via at least the human T2R16 and mouse T2R118 receptor. Figure S3 .
Figure 6. AMP-DNM stimulates GLP1 secretion through bitter receptors hT2R16 and T2R118 expressed in endocrine-intestinal cells. STC1 cells were stably transfected with taste receptors or GFP as control. Cells were exposed to different stimulus and intracellular Ca 2+ response was fluorimetrically monitored (difference of fluorescent signal intensity compared to control expressed in arbitrary fluorescent units (Dif AFU)) and GLP1 in medium was quantified by ELISA. A) Chemical structure of L-ido-AMP-DNM. B) Dif AFU after glutamate stimulation of GFP and hT2R16 overexpressing cells. C) Dif AFU after salicin stimulation of GFP and hT2R16 overexpressing cells. D) Dif AFU after AMP-DNM stimulation of GFP and hT2R16 overexpressing cells E) Medium GLP1 after AMP-DNM stimulation. F) Dif AFU after L-ido-AMP-DNM stimulation of GFP and hT2R16 overexpressing cells. G) Medium GLP1 after L-ido-AMP-DNM stimulation. H) Dif AFU after AMP-DNM stimulation of GFP and T2R118 overexpressing cells. I) Medium GLP1 in medium of GFP and T2R118 overexpressing cells after AMP-DNM stimulation, corrected for background GLP1. All data are presented as mean ± SEM, for related information see also
DISCUSSION
The present study shows that the well-tolerated iminosugar AMP-DNM exerts part of its beneficial metabolic effects in obese animals through the GLP1 pathway. Previously, we showed that AMP-DNM improved glucose metabolism and satiety and decreased body weight in different models of obesity. Here we explored the possibility that additional to its capacity as an enzyme inhibitor of GSLs metabolism, AMP-DNM modulates energy metabolism through influencing gastrointestinal endocrine factors acting on neural circuits controlling energy metabolism. Ig administration of AMP-DNM, but not icv infusion, significantly reduced food intake, corrected plasma glucose levels and increased fat oxidation in obese ZDF rats, indicating that the peripheral action of AMP-DNM is essential to trigger changes in energy intake. Similar potent effects were observed in diet-induced obese (DIO) mice, AMP-DNM increased satiety, decreased body weight and fat mass and improved glucose tolerance exceeding that of pair-fed animals. Previously we showed that AMP-DNM improves insulin sensitivity and corrects glycemic control in leptin deficient animals (ob/ob) (van Eijk et al. Other beneficial effects of AMP-DNM in obese rodents include increased fat oxidation, decreased hepatic triglycerides and reduced food intake (Langeveld et al., 2012; Lombardo et al., 2012) . High doses of the structurally related N-butyldeoxynojirimycin (NB-DNJ) also cause weight loss as a result of reduced food consumption in healthy lean and ob/ob mice. Mice treated with N-butyl-deoxygalactonojirimycin, inhibiting GCS on a par with NB-DNJ, did not lose weight (Priestman et al., 2008) . Notably, the L-idose analogue of AMP-DNM did not reduce food intake or increase fat oxidation, despite its capacity of equally inhibiting synthesis of glycosphingolipids, suggesting that not all the observed 235 8 metabolic effects are directly mediated by a modulation of GSLs content. Our present study sheds further light on underlying mechanisms by which AMP-DNM exerts its pleiotropic effects in obese rodents and demonstrates that AMP-DNM impacts on obese animals in multiple ways.
A second key observation was that peripheral administration of AMP-DNM induced hypothalamic and brainstem activation, specifically in the ARC, DMH and NTS and induced increase of GLP1 in plasma of animals receiving the iminosugar by gavage but not by icv administration. More specific, AMP-DNM induced POMC expression in the ARC and PPG expression in the NTS. GLP1 is synthesized in the ileum by enteroendocrine L-cells and in the brainstem NTS after nutrient ingestion and participates in numerous physiological functions improving glucose metabolism and stimulating satiety. The inactive precursor of GLP1 is processed to the active forms GLP1-(7-37) and GLP1-(7-36)NH2, each with short half lives in blood due to degradation by dipeptidyl peptidase-4 (DPP-4) (Donnelly, 2012) . DPP-4 inhibitors and GLP1 mimetics have been proven beneficial for the treatment of type 2 diabetes and body weight loss (Engelstoft and Schwartz, 2016) . It was shown that peripheral administration of exendin-4 (agonist of GLP1r) or GLP1 increases C-fos expression in the ARC and the caudal part of the NTS (Baraboi et al., 2011), moreover GLP1 increases gastric vagal afferent activity by acting on GLP1r located in vagal nerve endings (Bucinskaite et al., 2009; Nakagawa et al., 2004) . The NTS receives sensory vagal inputs that constitute a major neuronal connection between the gut and the brain (Grill and Hayes, 2012) . Thus, our next aim was to further elucidate the role of GLP1 signaling in the AMP-DNM induced metabolic improvements. We first established the importance of GLP1 and its receptor (GLP1r) in AMP-DNM induced reduced food intake. GLP1rKO mice with diet-induced obesity were found not to respond to AMP-DNM by decreasing food intake. To test the contribution of GLP1r in the brain GLP1r KD ΔNkx2.1 mice with conditional absence of GLP1r in hypothalamic neurons were examined. These mice also did not reduce their food intake after AMP-DNM treatment. These findings suggested that the central GLP1r is crucial in mediating the satiety-promoting effect of AMP-DNM. Furthermore, icv infusion of exendin-9 in DIO wt mice prohibited reduced food intake in response to AMP-DNM. Of note, the beneficial effects of AMP-DNM on glycemic control were not prevented by genetic ablation of central GLP1r or its blockade by exendin-9. Thus, the promotion of satiety in obese mice by AMP-DNM, but not the corrections in glucose homeostasis, are critically dependent on central GLP1r. Similar data were previously shown after infusion of the GLP1r agonist Liraglutide. It was shown that Liraglutide exert its satiety effects, but not its glucose sensitizing effects, through the GLP1r in brain (Sisley et al., 2014) .
AMP-DNM activation of central GLP1r also governed BAT activation, as exendin-9 icv administration prevented these responses to AMP-DNM in DIO wt mice and they were not triggered in the BAT of DIO GLP1r KD ΔNkx2.1 mice. The central GLP1 system has been implicated in the control of BAT activation and thermogenesis control by increasing sympathetic output to the BAT Lockie et al., 2012) . Consistently, the ARC and DMH of DIO GLP1r KD ΔNkx2.1 mice showed lack of increased C-fos activation by AMP-DNM. POMC expression in the hypothalamus was not increased by AMP-DNM in DIO GLP1r KD ΔNkx2.1 mice. GLP1 neurons in the NTS maintain projections with the paraventricular nucleus of the hypothalamus, DMH and ARC, moreover the GLP1r is expressed in ARC NPY and POMC neurons (Baggio and Drucker, 2014). Collectively these findings indicate that the brain GLP1r mediates the activation of anorexigenic neurons by AMP-DNM as well as its activation of BAT.
Induction of GLP1 secretion by dietary and gut microbiota-derived metabolites is generally attributed to the activation of fatty acid receptors, as well as the CaSR and the bile acid sensing TGR5 receptor at the basolateral membrane (Engelstoft and Schwartz, 2016) . Importantly, some bitter agents also potently induce secretion of GLP1, as reported earlier and again demonstrated here for AMP-DNM (Jang et al., 2007; Jeon et al., 2008) . As candidate AMP-DNM sensors inducing GLP1 secretion, we considered the endogenous bitter taste receptor in mice, T2R118. Transfection of STC1 cells with mouse T2R118 made these cells secrete GLP1 into the medium. Very recently it was reported that activation of bitter taste receptor T2R138 stimulates GLP1 release from enteroendocrine L-cells (Pham et al., 2016) . Thus, binding of AMP-DNM to T2R118, and probably additional taste receptors, in the ileum of mice is likely the trigger to induce GLP1. In conclusion, our investigation documents the induction by AMP-DNM of GLP1 that mediates improvements in regulation of energy intake and activation of BAT. Our findings provide a further mechanistic basis for the broad therapeutic effect of AMP-DNM in rodent models of obesity and type 2 diabetes mellitus.
EXPERIMENTAL PROCEDURES
Animals. All animals were kept in individual cages at constant temperature (23± 2 °C), submitted to a 12/12h light/dark cycle. They were exposed to ad libitum food and water before and after the experimental procedures, except when mentioned otherwise. All animal protocols were approved by the Institutional Animal Welfare Committee of the Academic Medical Center and the Royal Netherlands Academy of Arts and Science, Amsterdam and the Leiden University Medical Center, Leiden (The Netherlands). Nkx2.1-cre GLP1r flox/flox mice were generated after backcrossing GLP1r lox/lox mice (Sisley et al., 2014) with Nkx2.1-Cre mice (Jackson Laboratory, Bar Harbor, USA). Nkx2.1-cre mice were used as wt control.
Iminosugars. AMP-DNM and L-ido-AMP-DNM were synthesized at the Leiden Institute of Chemistry as described earlier (Wennekes et al., 2010) .
Surgical procedures. Wistar and Zucker Diabetic Fatty (ZDF) rats were anesthetized with a mixture of 0.4 ml/kg Dormicum (Roche, Almere, The Netherlands) and 0.8 ml/kg Hypnorm (Janssen, High Wycombe, Buckinghamshire, UK). For infusions in the CNS, Wistar and ZDF rats were implanted with icv stainless steel guide cannulas in the lateral ventricle using the following stereotaxic coordinates: AP -0.9, L +2.0 and V -3.4, tooth bar (-2.5mm). For the peripheral infusions, Wistar and ZDF rats were implanted with ig silicon cannulas in the stomach. Additional groups of Wistar and ZDF rats were implanted with an ig and a right jugular vein catheter during the same surgery for simultaneous intragastric infusions and iv blood sampling (Girault et al., 2012) . Analgesic Buprecare (Recipharm, Lancashire, UK) was administered after the animals woke up from the surgery; experiments were performed after a recovery period of 7-10 days post-operative recovery. C57Bl/6J mice were implanted with icv cannulas in the lateral ventricle connected to osmotic minipumps (Model 1004, Alzet, CA, USA) as previously described . The minipumps were filled with exendin-9 or artificial cerebrospinal fluid (aCSF) and assured continuous delivery of 0.72 mmol/kg/day exendin-9 (Knauf et al., 2005) .
Iminosugar infusions in rats.
After the post-surgical recovery period, lean male Wistar rats (8-10 weeks old, Harlan, Horst, The Netherlands) and male ZDF rats (8-10 weeks old, Charles River, Chatillon-sur-Chalaronne, France) were transferred to an indirect calorimetry system (PhenoMaster/LabMaster, TSE Systems, Bad Homburg, Germany). Food intake, 237 8 locomotor activity, energy expenditure (EE), respiratory exchange ratio (RER) and fatty acid and carbohydrate oxidation rates were assessed individually as previously described (Frayn, 1983; Girault et al., 2012) . After a 4 day acclimation period, the rats were icv (0.03 mg/kg) or ig (100 mg/kg) infused with AMP-DNM (Wistar group: icv=8, ig=4; ZDF group: icv=5, ig=7), L-ido-AMP-DNM (Wistar groups: icv=7, ig=4; ZDF group: icv=4, ig=5) or vehicle (Wistar groups: icv=6, ig=4; ZDF group: icv=5, ig=5) on days 5 and 7, the animals were not disturbed during days 6, 8 and 9 until they were sacrificed by CO2 euthanasia. An additional pair-fed ZDF group was administered ig AMP-DNM (n=6) or vehicle (n=5). Tail cuts for blood sampling were performed on day 5 as well as on day 9 for plasma hormone measurement and glucose assessment using a glucometer (Freestyle, Abbott, Hoofddorp, The Netherlands).
Additional Wistar and ZDF rats were implanted with ig and iv catheters. After a 7-10 day recovery period food was removed overnight on the evening before the day of the experiment, at the same time rats were also connected to a metal collar, allowing the next day to perform sampling and infusions out of reach from the rats. In this way, blood sampling was performed simultaneous with AMP-DNM or vehicle ig infusions, without stressing the animals. After 10 minutes of the AMP-DNM (100mg/kg) or vehicle ig infusions, food was given back and 2h later food intake was measured. Blood samples for plasma GLP1 concentration assessment were taken at -60, 20, 40, and 60 minutes after infusions.
Iminosugar infusions in mice. C57Bl/6J and ob/ob mice (8-10 weeks old, Envigo, Venray, The Netherlands) were fasted for 3 hours and then ig infused with AMP-DNM (100 mg/ kg, C57Bl/6J n=4, ob/ob n=8), L-ido-AMP-DNM (100 mg/kg, C57Bl/6J n=4, ob/ob n=6) or vehicle (C57Bl/6J n=7, ob/ob n=5). Ninety minutes later the mice were sacrificed and transcardially perfused with 250 ml of 0.9% (w/v) saline solution followed by 4 % paraformaldehyde in phosphate buffer (0.1 M, pH 7.2). Brains were processed for immunohistochemistry. Additional groups of mice received oral gavage of AMP-DNM (100 mg/ kg, C57Bl/6J n=7, ob/ob n=6) or vehicle (C57Bl/6J n=5, ob/ob n=5) 3 hours after food had been removed. Two hours later the mice were sacrificed, their brains were removed and frozen for analysis.
Chronic AMP-DNM administration to mice. C57Bl/6J mice were fed with a high fat diet (HFD, Research Diets D12492, NJ, USA) for 12 weeks and then were placed individually in metabolic cages for 3 days for basal assessment of metabolic parameters. Afterwards animals were fed with a HFD (n=10) or a HFD with AMP-DNM (n=9) mixed in the food (HFD+AMP-DNM, 100mg/kg) for 4 weeks. Body weight and food intake was measured daily. A pair-fed group (n=5) was included, matched to HFD+AMP-DNM. Additional groups of animals were implanted with an icv cannula, via which they received aCSF (n=5) or exendin-9 (n=7). In the second week of treatment an oral glucose tolerance test (OGTT) was performed. In week 4 animals were fasted for 4 hours and were infused with a radioactive mixture of glycerol tri[ 3 H]oleate-labelled triglyceride (TG)-rich lipoprotein-like particles and 2-[1-
14 C]deoxy-d-glucose ([ 14 C]DG) to assess TG and glucose clearance as previously described . Mice were sacrificed by cervical dislocation and immediately after their body composition (lean and fat mass) was assessed using an EchoMRI-100 (EchoMRI, Houston, TX, USA) and organs were collected for further analysis.
GLP1r KD
ΔNkx2.1 , GLP1r KO and wt mice were fed with a HFD for 8 weeks and then individually placed in metabolic cages for 4 days for basal metabolic parameter assessment. Afterwards, the animals were divided in HFD fed group (GLP1r KD ΔNkx2.1 n=5, GLP1r KO n=6
and wt n=13) and HFD+AMP-DNM (100 mg/kg) fed group (GLP1r KD ΔNkx2.1 n=6, GLP1r KO n=6 and wt n=14) and remained in the metabolic cages for another 5 days. After this period, animals were returned to their home cages and fed with the same diets for 4 weeks. An OGTT was performed in week 3 after exposure to HFD+AMP-DNM diet. At the end of week 4, animals were fasted for 4 hours and animals fed with a HFD received a vehicle oral gavage, while the animals fed with a HFD+AMP-DNM received an AMP-DNM oral gavage. Next, mice were sacrificed, their brains and BAT removed for immuno-histochemistry and gene expression analysis.
GLP1 measurement. Processed active forms of GLP1 were measured in blood samples and cell media immediately incubated in DPP-IV inhibitor Ile-Pro-Ile (Sigma, St Louis, USA) and kept on ice until centrifugation. After centrifugation, the plasma or cell media was stored at -80°C until measurement of active GLP1 by an ELISA (Millipore, Darmstadt, Germany).
BAT and brain immunohistochemistry. Sample preparation, immunohistochemical and microdissection procedures used are described in the Supplemental Experimental Procedures.
Laser capture microdissection procedures. C57Bl/6J and ob/ob mice frozen brains were cut in 20µm coronal sections, attached to PEN slides 1.0 mm (Zeiss, Gottingen, Germany) and stored at -80°C until the moment of laser dissection. All working surfaces were treated with RNaseZAP (Sigma, St Louis, USA) and all glassware was baked at 280°C overnight to inactivate RNases. Just before the laser capture microdissection (LCM), the sections were stained with 0.1% cresyl violet for 45 seconds and rinsed briefly in RNase free H2O. Afterwards the tissue was dehydrated in 70% and 90% EtOH for 30 seconds each, followed by 1 minute dehydration in 100% EtOH. After 1 minute EtOH evaporation, ARC, DMH, LH and NTS were dissected using a PALM microdissection microscope (ZEISS, Gottingen, Germany). The dissected nuclei were stored in Trizol Reagent (Life Technologies, California, USA) in RNase free adhesive caps (ZEISS, Gottingen, Germany) at -80°C until further RNA isolation. In addition, whole hypothalamus (HT) and brainstem (BT) were dissected from GLP1r KD ΔNkx2.1 and wt mice for RNA isolation. Details of RNA isolation and further analysis are provided in Supplemental Experimental Procedures. and after compound application, fluorescent was measured for an additional 8 minutes. Fluorescent responses were measured every second after ligand administration and then corrected for the initial background fluorescence. Fluorescent differences were expressed as delta arbitrary fluorescent units (AFU), which was defined as the difference between the maximum and minimum fluorescent values in every assay (Sakurai et al., 2010) . Finally, the medium was collected for further active GLP1 assessment.
Statistical analysis.
Results are expressed as the mean ± SEM. Two-way ANOVA, one-way ANOVA and T-test analysis were performed using SPSS statistical package version 19 and GraphPad Prism 6. Pairwise comparisons were evaluated with a Tukey and LSD post-hoc test. Significant values were set at p<0.05. Active GLP1 and OGTT glucose concentrations were analyzed by an ANOVA of repeated measures with 2 between subject factors: Genotype and Substance. An adjustment of Bonferroni was performed with significant values set as p<0.05. 
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Dissection of brain areas
GLP1r ΔNkx2.1 KO and wt mice brainstems were isolated from the rest of the brain by separating the hindbrain from the cortical lobes at the level of inferior colliculus. The pons and cerebellum were separated from the brainstem and the brainstems were cut slightly lower of the obex to separate it from the spinal cord. The hypothalamus was dissected by introducing blunt curved forceps at the level of the mammillary nucleus and separating it from the rest of the brain.
RNA isolation and RT-PCR
RNA from the LCM brain nuclei was isolated after tissue homogenization with Trizol by vortexing repeatedly for a few seconds. RNase free chloroform was added and the transparent RNA phase was taken in a new RNAse free tube where isopropanol was added and stored at 4°C overnight for RNA precipitation. After centrifugation, the pellet was washed with 75% EtOH and air-dried until solubilization. RNA isolation of mice brown adipose tis-243 8
